Study of how a light treatment causes immune cell death
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+).
- You have been receiving extracorporeal photochemotherapy for at least 1 month.
- The treatment is for one of these: graft-versus-host disease after bone marrow transplant, rejection after solid organ transplant, or cutaneous T-cell lymphoma.
- You must have legal ability to take part and be able to follow study steps.
- You need social security health coverage.
- You cannot be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
This early-phase trial tests lab-made “memory” immune T cells that target Epstein-Barr virus (EBV). It may help people whose EBV infection has caused lymphomas or serious complications after a transplant.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This trial studies a treatment called ECP to help immune-related side effects (irAEs) that did not improve with standard steroid treatment. It may help control symptoms and change immune activity to reduce ongoing harm from immunotherapy.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.